Aura Biosciences to Present Updated Phase 2 Data Evaluating Suprachoroidal Administration of Belzupacap Sarotalocan (Bel-sar) for the First-Line Treatment of Patients with Early-Stage Choroidal Melanoma at AAO 2023
31 Octubre 2023 - 2:05PM
Business Wire
Aura Biosciences Inc. (NASDAQ: AURA), a clinical-stage
biotechnology company developing a novel class of virus-like drug
conjugate (VDC) therapies for multiple oncology indications, today
announced that updated data from the Phase 2 trial evaluating the
safety and efficacy of suprachoroidal (SC) administration using its
first VDC product candidate, bel-sar, for the first-line treatment
of adult patients with early-stage choroidal melanoma will be
presented at the upcoming American Academy of Ophthalmology (AAO)
2023 Annual Meeting being held November 3-6, 2023, in San
Francisco.
Details for the paper presentation are as follows:
Title: A Phase 2 Trial of Belzupacap Sarotalocan, a
Targeted Investigational Therapy for Choroidal Melanoma via
Suprachoroidal Administration Presenter: Carol L. Shields,
MD, Wills Eye Hospital Session #: PA069 Location #:
WEST 2006 Date/Time: Monday, November 6, 2023, from 2:54
p.m. to 3:01 p.m. Eastern Time (11:54 a.m. to 12:01 p.m. Pacific
Time)
The presentation will be available here on Monday, November 6,
2023, following the presentation.
About Aura Biosciences
Aura Biosciences, Inc. is a clinical-stage biotechnology company
developing virus-like drug conjugates (VDCs), a novel class of
therapies, for the treatment of multiple oncology indications.
Aura’s lead VDC candidate, belzupacap sarotalocan (bel-sar;
AU-011), consists of a virus-like particle conjugated with an
anti-cancer agent. Bel-sar is designed to selectively target and
destroy cancer cells and activate the immune system with the
potential to create long-lasting, anti-tumor immunity. Bel-sar is
currently in development for ocular cancers, and Aura has initiated
activities for the global Phase 3 trial evaluating first-line
treatment of early-stage choroidal melanoma, a vision- and
life-threatening form of eye cancer where standard of care with
radiotherapy leaves patients with severe comorbidities, including
major vision loss. Aura plans to pursue development of bel-sar
across its ocular oncology franchise including for the treatment of
patients with choroidal metastasis. In addition, leveraging Aura’s
technology platform, Aura is developing bel-sar more broadly across
multiple cancers, including in patients with non-muscle invasive
bladder cancer. Aura is headquartered in Boston, MA.
For more information, visit aurabiosciences.com, or follow us on
Twitter and LinkedIn
View source
version on businesswire.com: https://www.businesswire.com/news/home/20231031579720/en/
Investor and Media Contact: Alex Dasalla Head of Investor
Relations and Corporate Communications
adasalla@aurabiosciences.com
Aura Biosciences (NASDAQ:AURA)
Gráfica de Acción Histórica
De Abr 2024 a May 2024
Aura Biosciences (NASDAQ:AURA)
Gráfica de Acción Histórica
De May 2023 a May 2024